Form 4 for KURA Kura Oncology, Inc.
Accepted 2025-11-14 00:00:00 ET · period of report 2025-11-13 · accession 0001193125-25-283564 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-14 | 2025-11-14 | KURA | Powl Brian T. | Chief Commercial Off | S - Sale | $11.18 | -8,887 | 139.7K | -6% | -$99.4K | |
| 2025-11-14 | 2025-11-13 | KURA | Powl Brian T. | Chief Commercial Off | A - Grant | $0.00 | +48.9K | 148.6K | +49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-14 | S | D | 8,887 | $11.18 | 139,689 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-13 | A | A | 48,900 | $0.00 | 148,576 | D | — | — | (F1) Grant of Restricted Stock Units (RSUs). The RSUs vest 50% immediately and 50% on 11/13/26. |